Cormedix Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cormedix Inc. on October 30, 2015, reporting an event that occurred on October 26, 2015. The filing addresses a change in the company's principal officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance updates and does not contain financial performance data.
Material Changes
Effective October 26, 2015, the Board of Directors appointed James Altland as Interim Chief Financial Officer. Mr. Altland is serving as a consultant for Cormedix. Prior to this appointment, he served as Senior Vice President of Finance and Corporate Development at Onconova Therapeutics, Inc. from 2007 to 2014 and was previously a Partner with Tatum.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. It confirms there are no family relationships between Mr. Altland and other directors or officers, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Points
- Verify the specific terms of Mr. Altland's engagement as a consultant and Interim CFO.
- Confirm the status of the permanent CFO search and the expected duration of the interim appointment.
- Review subsequent filings for any financial updates or strategic shifts resulting from this leadership change.